PMV Pharmaceuticals annual r&d spending
2018
2019
2020
2021
2022
2023
2024
2025
PMV Pharmaceuticals R&D Spending Growth & History (PMVP)
PMV Pharmaceuticals's r&d spending was $69.9M for fiscal 2025.
View full PMV Pharmaceuticals company overviewPMV Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $69.9M | $11.3M | +19.39% |
| 2024 | 2024-12-31 | $58.5M | $2.6M | +4.73% |
| 2023 | 2023-12-31 | $55.9M | $3.9M | +7.50% |
| 2022 | 2022-12-31 | $52.0M | $15.5M | +42.46% |
| 2021 | 2021-12-31 | $36.5M | $12.6M | +52.48% |
| 2020 | 2020-12-31 | $23.9M | $3.2M | +15.29% |
| 2019 | 2019-12-31 | $20.8M | $6.9M | +49.85% |
| 2018 | 2018-12-31 | $13.9M | — | — |
PMV Pharmaceuticals quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $14.7M | −$3.7M | −20.24% |
| Q1 2026 | 2026-03-31 | $15.3M | −$2.1M | −12.10% |
| Q4 2025 | 2025-12-31 | $15.8M | $2.1M | +14.96% |
| Q3 2025 | 2025-09-30 | $18.2M | $1.3M | +7.45% |
| Q2 2025 | 2025-06-30 | $18.4M | $3.8M | +25.79% |
| Q1 2025 | 2025-03-31 | $17.4M | $4.3M | +32.27% |
| Q4 2024 | 2024-12-31 | $13.8M | $383,000 | +2.86% |
| Q3 2024 | 2024-09-30 | $16.9M | $3.4M | +24.74% |
| Q2 2024 | 2024-06-30 | $14.6M | $785,000 | +5.67% |
| Q1 2024 | 2024-03-31 | $13.2M | −$1.9M | −12.52% |
| Q4 2023 | 2023-12-31 | $13.4M | −$1.6M | −10.92% |
| Q3 2023 | 2023-09-30 | $13.6M | −$80,000 | −0.59% |
| Q2 2023 | 2023-06-30 | $13.8M | $2.4M | +20.77% |
| Q1 2023 | 2023-03-31 | $15.1M | $3.2M | +27.35% |
| Q4 2022 | 2022-12-31 | $15.0M | $2.9M | +23.48% |
| Q3 2022 | 2022-09-30 | $13.7M | $4.5M | +49.16% |
| Q2 2022 | 2022-06-30 | $11.5M | $3.8M | +49.56% |
| Q1 2022 | 2022-03-31 | $11.8M | $4.3M | +57.81% |
| Q4 2021 | 2021-12-31 | $12.2M | $6.0M | +96.81% |
| Q3 2021 | 2021-09-30 | $9.2M | $3.2M | +52.90% |
| Q2 2021 | 2021-06-30 | $7.7M | $1.9M | +32.05% |
| Q1 2021 | 2021-03-31 | $7.5M | $1.5M | +25.94% |
| Q4 2020 | 2020-12-31 | $6.2M | — | — |
| Q3 2020 | 2020-09-30 | $6.0M | $1.1M | +22.41% |
| Q2 2020 | 2020-06-30 | $5.8M | — | — |
| Q1 2020 | 2020-03-31 | $6.0M | — | — |
| Q3 2019 | 2019-09-30 | $4.9M | — | — |
PMV Pharmaceuticals r&d spending trends
Over the last five fiscal years, PMV Pharmaceuticals's r&d spending increased from $23.9M to $69.9M, a change of $45.9M. The latest reported quarter, Q2 2026, shows $14.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review PMV Pharmaceuticals source filings ↗